Search tips
Search criteria 


Logo of iaiPermissionsJournals.ASM.orgJournalIAI ArticleJournal InfoAuthorsReviewers
Infect Immun. 1995 August; 63(8): 2854–2858.
PMCID: PMC173387

Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague.


The gene encoding V antigen from Yersinia pestis was cloned into the plasmid expression vector pGEX-5X-2. When electroporated into Escherichia coli JM109, the recombinant expressed V antigen as a stable fusion protein with glutathione S-transferase. The glutathione S-transferase-V fusion protein was isolated from recombinant E. coli and cleaved with factor Xa to yield purified V antigen as a stable product. Recombinant V antigen was inoculated intraperitoneally into mice and shown to induce a protective immune response against a subcutaneous challenge with 3.74 x 10(6) CFU of virulent Y. pestis. Protection correlated with the induction of a high titer of serum antibodies and a T-cell response specific for recombinant V antigen. These results indicate that V antigen should be a major component of an improved vaccine for plague.

Full Text

The Full Text of this article is available as a PDF (381K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Brubaker RR, Sample AK, Yu DZ, Zahorchak RJ, Hu PC, Fowler JM. Proteolysis of V antigen from Yersinia pestis. Microb Pathog. 1987 Jan;2(1):49–62. [PubMed]
  • Cavanaugh DC, Elisberg BL, Llewellyn CH, Marshall JD, Jr, Rust JH, Jr, Williams JE, Meyer KF. Plague immunization. V. Indirect evidence for the efficacy of plague vaccine. J Infect Dis. 1974 May;129(Suppl):S37–S40. [PubMed]
  • Marshall JD, Jr, Bartelloni PJ, Cavanaugh DC, Kadull PJ, Meyer KF. Plague immunization. II. Relation of adverse clinical reactions to multiple immunizations with killed vaccine. J Infect Dis. 1974 May;129(Suppl):S19–S25. [PubMed]
  • McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine. 1992;10(2):75–88. [PubMed]
  • Meyer KF. Effectiveness of live or killed plague vaccines in man. Bull World Health Organ. 1970;42(5):653–666. [PubMed]
  • Motin VL, Nakajima R, Smirnov GB, Brubaker RR. Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide. Infect Immun. 1994 Oct;62(10):4192–4201. [PMC free article] [PubMed]
  • Nakajima R, Brubaker RR. Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha. Infect Immun. 1993 Jan;61(1):23–31. [PMC free article] [PubMed]
  • Oyston PC, Williamson ED, Leary SE, Eley SM, Griffin KF, Titball RW. Immunization with live recombinant Salmonella typhimurium aroA producing F1 antigen protects against plague. Infect Immun. 1995 Feb;63(2):563–568. [PMC free article] [PubMed]
  • Price SB, Cowan C, Perry RD, Straley SC. The Yersinia pestis V antigen is a regulatory protein necessary for Ca2(+)-dependent growth and maximal expression of low-Ca2+ response virulence genes. J Bacteriol. 1991 Apr;173(8):2649–2657. [PMC free article] [PubMed]
  • Price SB, Leung KY, Barve SS, Straley SC. Molecular analysis of lcrGVH, the V antigen operon of Yersinia pestis. J Bacteriol. 1989 Oct;171(10):5646–5653. [PMC free article] [PubMed]
  • Sato K, Nakajima R, Hara F, Une T, Osada Y. Preparation of monoclonal antibody to V antigen from Yersinia pestis. Contrib Microbiol Immunol. 1991;12:225–229. [PubMed]
  • Simpson WJ, Thomas RE, Schwan TG. Recombinant capsular antigen (fraction 1) from Yersinia pestis induces a protective antibody response in BALB/c mice. Am J Trop Med Hyg. 1990 Oct;43(4):389–396. [PubMed]
  • Straley SC, Cibull ML. Differential clearance and host-pathogen interactions of YopE- and YopK- YopL- Yersinia pestis in BALB/c mice. Infect Immun. 1989 Apr;57(4):1200–1210. [PMC free article] [PubMed]
  • Une T, Brubaker RR. Roles of V antigen in promoting virulence and immunity in yersiniae. J Immunol. 1984 Oct;133(4):2226–2230. [PubMed]
  • Une T, Nakajima R, Brubaker RR. Roles of V antigen in promoting virulence in Yersiniae. Contrib Microbiol Immunol. 1987;9:179–185. [PubMed]
  • Williamson ED, Titball RW. A genetically engineered vaccine against the alpha-toxin of Clostridium perfringens protects mice against experimental gas gangrene. Vaccine. 1993 Sep;11(12):1253–1258. [PubMed]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)